Intersect ENT: Q3 Earnings Insights

Shares of Intersect ENT XENT remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share increased 17.07% year over year to ($0.34), which beat the estimate of ($0.45).

Revenue of $22,720,000 declined by 5.55% from the same period last year, which beat the estimate of $21,370,000.

Outlook

Intersect ENT hasn't issued any earnings guidance for the time being.

Q4 revenue expected to be between $26,991,000 and $28,579,000.

Conference Call Details

Date: Nov 02, 2020

Time: 08:30 AM

ET Webcast URL: https://78449.choruscall.com/dataconf/productusers/xent/mediaframe/41323/indexr.html

Price Action

Company's 52-week high was at $31.46

52-week low: $5.97

Price action over last quarter: down 20.72%

Company Profile

Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.